CL2019003402A1 - Composiciones sólidas para administración oral. - Google Patents

Composiciones sólidas para administración oral.

Info

Publication number
CL2019003402A1
CL2019003402A1 CL2019003402A CL2019003402A CL2019003402A1 CL 2019003402 A1 CL2019003402 A1 CL 2019003402A1 CL 2019003402 A CL2019003402 A CL 2019003402A CL 2019003402 A CL2019003402 A CL 2019003402A CL 2019003402 A1 CL2019003402 A1 CL 2019003402A1
Authority
CL
Chile
Prior art keywords
oral administration
solid compositions
sglt2
glp
inhibitor
Prior art date
Application number
CL2019003402A
Other languages
English (en)
Inventor
Vegge Andreas
Schéele Susanne
Bjerregaard Simon
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59070439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019003402(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CL2019003402A1 publication Critical patent/CL2019003402A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPOSICIONES SÓLIDAS PARA ADMINISTRACIÓN ORAL QUE COMPRENDEN (I) UN DERIVADO DE GLP-1 Y EL INHIBIDOR DE SGLT2 DAPAGLIFLOZINA O (II) UN DERIVADO DE GLP-1 Y UNA SAL DE NAC EN COMBINACIÓN CON UN INHIBIDOR DE SGLT2.
CL2019003402A 2017-06-09 2019-11-22 Composiciones sólidas para administración oral. CL2019003402A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17175131 2017-06-09

Publications (1)

Publication Number Publication Date
CL2019003402A1 true CL2019003402A1 (es) 2020-03-20

Family

ID=59070439

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003402A CL2019003402A1 (es) 2017-06-09 2019-11-22 Composiciones sólidas para administración oral.

Country Status (28)

Country Link
US (2) US11167014B2 (es)
EP (1) EP3634468B1 (es)
JP (1) JP7239495B2 (es)
KR (1) KR20200015564A (es)
CN (1) CN110769846A (es)
AR (1) AR112015A1 (es)
AU (1) AU2018280875A1 (es)
BR (1) BR112019025769A2 (es)
CA (1) CA3064677A1 (es)
CL (1) CL2019003402A1 (es)
CO (1) CO2019013047A2 (es)
DK (1) DK3634468T3 (es)
ES (1) ES2938050T3 (es)
FI (1) FI3634468T3 (es)
HR (1) HRP20230075T1 (es)
HU (1) HUE060962T2 (es)
IL (1) IL270812B2 (es)
MA (1) MA49253A (es)
MX (1) MX2019013965A (es)
MY (1) MY197488A (es)
PE (1) PE20200606A1 (es)
PH (1) PH12019550249A1 (es)
PL (1) PL3634468T3 (es)
PT (1) PT3634468T (es)
RS (1) RS64045B1 (es)
SI (1) SI3634468T1 (es)
TW (1) TWI797133B (es)
WO (1) WO2018224689A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11622996B2 (en) 2018-05-07 2023-04-11 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
EP3746111B1 (en) 2018-02-02 2023-07-19 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
WO2020130502A1 (ko) * 2018-12-21 2020-06-25 (주)휴온스 엠파글리플로진 및 시타글립틴을 포함하는 약학적 조성물
JP2022545156A (ja) * 2019-08-07 2022-10-26 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬と、ｓｇｌｔ２阻害剤と、ｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物
US20220395559A1 (en) * 2019-11-07 2022-12-15 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
WO2023065231A1 (en) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
WO2023123063A1 (en) * 2021-12-29 2023-07-06 Guangzhou Dazhou Biomedicine Ltd. Oral delivery
EP4299052A1 (en) * 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and a permeation enhancer
CN114984191B (zh) * 2022-07-04 2022-10-25 北京惠之衡生物科技有限公司 一种多肽类药物口服递送组合物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
CA2361716C (en) 1999-02-05 2009-04-28 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
US7745414B2 (en) 2006-02-15 2010-06-29 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US10875826B2 (en) 2006-09-07 2020-12-29 Emisphere Technologies, Inc. Process for the manufacture of SNAC (salcaprozate sodium)
PE20090185A1 (es) 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
EP2147008A2 (en) 2007-05-18 2010-01-27 Bristol-Myers Squibb Company Crystal structures of sglt2 inhibitors and processes for preparing same
EP2679597A1 (en) 2007-09-05 2014-01-01 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US8685934B2 (en) 2009-05-27 2014-04-01 Bristol-Myers Squibb Company Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
CA2780941C (en) 2009-11-13 2018-06-12 Bristol-Myers Squibb Company Immediate release tablet formulations
WO2011080102A2 (en) 2009-12-16 2011-07-07 Novo Nordisk A/S Glp-1 analogues and derivatives
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN106117344B (zh) 2011-04-12 2020-11-03 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
WO2013032934A1 (en) 2011-08-26 2013-03-07 Aegis Therapeutics, Llc Compositions and methods thereof for oral administration of drugs
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
HRP20231613T1 (hr) 2012-03-22 2024-03-15 Novo Nordisk A/S Pripravci koji sadrže sredstvo za unošenje i njihova priprava
EP2863895B1 (en) * 2012-06-20 2021-04-14 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
JP6755175B2 (ja) 2013-03-20 2020-09-16 ノヴォ ノルディスク アー／エス インスリン投薬レジメン
WO2015155151A1 (en) 2014-04-07 2015-10-15 Novo Nordisk A/S Double-acylated glp-1 compounds
AU2016287843B2 (en) * 2015-07-02 2021-06-17 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CN110022935A (zh) 2016-11-28 2019-07-16 诺和诺德股份有限公司 用于心血管病况的德谷胰岛素
CN110099719A (zh) 2016-11-28 2019-08-06 诺和诺德股份有限公司 用于改善血糖控制以及减少急性和长期糖尿病并发症的德谷胰岛素
WO2018096164A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
JP2022545156A (ja) * 2019-08-07 2022-10-26 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬と、ｓｇｌｔ２阻害剤と、ｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11622996B2 (en) 2018-05-07 2023-04-11 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid

Also Published As

Publication number Publication date
IL270812B2 (en) 2024-01-01
KR20200015564A (ko) 2020-02-12
JP7239495B2 (ja) 2023-03-14
ES2938050T3 (es) 2023-04-04
MX2019013965A (es) 2020-01-23
AR112015A1 (es) 2019-09-11
CA3064677A1 (en) 2018-12-13
TWI797133B (zh) 2023-04-01
TW201904583A (zh) 2019-02-01
SI3634468T1 (sl) 2023-02-28
IL270812A (en) 2020-01-30
DK3634468T3 (da) 2023-02-06
RU2019139082A3 (es) 2021-09-16
FI3634468T3 (fi) 2023-02-19
RU2019139082A (ru) 2021-06-02
HUE060962T2 (hu) 2023-04-28
MY197488A (en) 2023-06-19
AU2018280875A1 (en) 2019-12-12
WO2018224689A2 (en) 2018-12-13
HRP20230075T1 (hr) 2023-03-17
WO2018224689A3 (en) 2019-02-28
BR112019025769A2 (pt) 2020-06-30
RS64045B1 (sr) 2023-04-28
EP3634468A2 (en) 2020-04-15
MA49253A (fr) 2020-04-15
CN110769846A (zh) 2020-02-07
PE20200606A1 (es) 2020-03-10
EP3634468B1 (en) 2022-12-14
CO2019013047A2 (es) 2020-04-01
US11167014B2 (en) 2021-11-09
PL3634468T3 (pl) 2023-03-13
US20220016216A1 (en) 2022-01-20
US20200147179A1 (en) 2020-05-14
IL270812B1 (en) 2023-09-01
PH12019550249A1 (en) 2020-07-13
PT3634468T (pt) 2023-03-28
JP2020522559A (ja) 2020-07-30

Similar Documents

Publication Publication Date Title
CL2019003402A1 (es) Composiciones sólidas para administración oral.
CL2020002919A1 (es) Inhibidores de mcl-1
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CO2018003134A2 (es) Composiciones para el cuidado bucal que comprenden un aminoácido básico, una combinación de fuentes de iones de zinc y un sistema quelante
GT201600070A (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
CL2016001131A1 (es) Uso de una combinación farmacéutica que comprende un compuesto inhibidor de mdm2 y uno o más agentes activos adicionales para el tratamiento del cáncer y composiciones farmacéuticas que comprenden dichas combinaciones.
SV2018005778A (es) Derivados aromaticos de sulfonamida
GT201600010A (es) Derivaods de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016002970A1 (es) Sales de adición de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo.
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
CO6640246A2 (es) Forma cristalina del inhibidor sglt2 bencilbenceno
SV2017005597A (es) Compuestos inhibidores de la señalizacion de la via de notch
CL2020001394A1 (es) Combinación de un derivado de 4-pirimidinsulfamida con un inhibidor de sglt-2 para el tratamiento contra enfermedades relacionadas con endotelina.
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
GT201700124A (es) Formulación de relación fija de insulina glargina/lixisenatida
AR102780A1 (es) Composiciones farmacéuticas, su preparación y sus usos
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
CL2017000230A1 (es) Composición adhesiva
CL2016001546A1 (es) Composición para el cuidado oral que comprende serina y al menos una sal de zinc.
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
CL2020002347A1 (es) Nuevo compuesto y composición farmacéutica que lo comprende
CU20180110A7 (es) Una composición que comprende pic para el tratamiento del cáncer
CL2020000586A1 (es) Moduladores de la expresión de enac.